Back then, research was small-scale, the evidence for allergy immunotherapy was limited and medical science was still in its infancy.
Over the decades, things have changed immensely, and ALK has been responsible for many of the innovations we now take for granted in our understanding of allergy and its treatment.
Completing the tablet portfolio
Most recently, we have developed a range of SLIT-tablets covering five of the most common global allergies – house dust mite, grass, trees from the birch tree family, ragweed and Japanese cedar.
Today, our R&D focus is on completing this portfolio and gaining approval for its use in all relevant ages – adults, adolescents and children.
We are also conducting several clinical trials to meet the specific local requirements of potentially important markets. In addition, we continue our pioneering work to investigate the benefits of SLIT-tablets in the prevention and treatment of allergic asthma.
